Actelion at neutral by Merrill

Actelion was retained at a neutral rating by Merrill Lynch analyst Erica Whittaker after Myogen published positive top-line data from the Aries-1 phase 3 study, showing that ambrisentan significantly improved exercise capacity in pulmonary hypertension with no cases of elevated liver enzymes. The analyst expects ambrisentan to be considered a second generation Tracleer, due mainly to its safety. Approval is expected in the first half of 2007. Shares of the Allschwil, Switzerland, biopharmaceutical company were up CHF10.00, or 8.06%, at CHF135 on volume of 833,696 shares versus the three-month running average of 139,779 shares. (SWX: ATLN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.